key: cord-1025042-ejprlf5v
authors: Beck, Evan J.; Hsieh, Yu-Hsiang; Fernandez, Reinaldo E.; Dashler, Gaby; Egbert, Emily R.; Truelove, Shawn A.; Garliss, Caroline; Wang, Richard; Bloch, Evan M.; Shrestha, Ruchee; Blankson, Joel; Cox, Andrea L.; Manabe, Yukari C.; Kickler, Thomas; Rothman, Richard E.; Redd, Andrew D.; Tobian, Aaron A. R.; Milstone, Aaron M.; Quinn, Thomas C.; Laeyendecker, Oliver
title: Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department
date: 2022-03-16
journal: J Clin Microbiol
DOI: 10.1128/jcm.02390-21
sha: a9c59952a98e926df20812cceb705502deea4514
doc_id: 1025042
cord_uid: ejprlf5v

Emergency departments (EDs) can serve as surveillance sites for infectious diseases. The objective of this study was to determine the burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to monitor the prevalence of vaccination against coronavirus disease 2019 (COVID-19) among patients attending an urban ED in Baltimore City. Using 1,914 samples of known exposure status, we developed an algorithm to differentiate previously infected, vaccinated, and unexposed individuals using a combination of antibody assays. We applied this testing algorithm to 4,360 samples from ED patients obtained in the spring of 2020 and 2021. Using multinomial logistic regression, we determined factors associated with infection and vaccination. For the algorithm, sensitivity and specificity for identifying vaccinated individuals were 100% and 99%, respectively, and 84% and 100% for previously infected individuals. Among the ED subjects, seroprevalence to SARS-CoV-2 increased from 2% to 24% between April 2020 and March 2021. Vaccination prevalence rose to 11% by mid-March 2021. Marked differences in burden of disease and vaccination coverage were seen by sex, race, and ethnicity. Hispanic patients, though accounting for 7% of the study population, had the highest relative burden of disease (17% of total infections) but with similar vaccination rates. Women and white individuals were more likely to be vaccinated than men or Black individuals. Individuals previously infected with SARS-CoV-2 can often be differentiated from vaccinated individuals using a serologic testing algorithm. The utility of this algorithm can aid in monitoring SARS-CoV-2 exposure and vaccination uptake frequencies and can potentially reflect gender, race, and ethnic health disparities.

Currently, three vaccines for COVID-19 have been authorized by the U.S. Food and Drug Administration (6) . The authorized vaccines from Pfizer, Moderna, and Johnson & Johnson each elicit an immune response against the spike protein of the SARS-CoV-2 virion (7) (8) (9) . As of 1 January 2022, 80% of persons aged $5 years have received at least one dose of a COVID-19 vaccine in the United States (10) . This uptake, however, has varied dramatically by race, socioeconomic status, and geographic location (11) (12) (13) .

In contrast to vaccinated individuals, previously infected patients have antibodies to several parts of the virus, including the spike and nucleocapsid proteins (14) . By comparing the results of serologic assays that detect antibodies to either spike (S1), the spike glycoprotein receptor-binding domain (RBD), or the nucleocapsid (N), it should be possible to distinguish between previously SARS-CoV-2-infected (either infected alone or infected and then vaccinated), vaccinated (with no evidence of prior infection), and uninfected individuals.

Emergency departments (EDs) have historically played a critical role in prior epidemics and pandemics (15) (16) (17) . Although case reporting can provide an estimate of populationlevel seroprevalence, relying on case reporting alone may underestimate the burden of infection, emphasizing the need for accurate serologic assessment of seroprevalence (18) . The goal of this study was to develop an algorithm to differentiate vaccinated, previously infected, and unexposed individuals using standard enzyme-linked immunosorbent assay (ELISA) and lateral flow assay (LFA) technology.

Ethics statement. This study used blood samples from studies approved by The Johns Hopkins University (JHU) School of Medicine Institutional Review Board (IRB00245545, IRB00247886, IRB00091667, IRB00250798, IRB00249350, and NA_00085477). Samples from the Moderna vaccine trial were provided as part of the Division of Microbiology and Infectious Diseases protocol 20-0003. For those studies, all individuals provided written informed consent. The JHU School of Medicine Institutional Review Board (IRB00083646 and CIR00016268) approved the deidentified serosurvey performed on waste material. All studies were conducted according to the ethics standards of the Helsinki Declaration of the World Medical Association.

Samples for algorithm validation. Three sample sets from individuals with known previous infection with and vaccination against SARS-CoV-2 were used to validate the antibody testing algorithm (Table 1) . Samples from individuals with known vaccination were drawn from a phase 1 trial (8) (n = 68) and vaccinated health care professionals (HCP, n = 360) (19, 20) . The 494 samples from individuals known to have been infected by SARS-CoV-2 were drawn from three cohorts: convalescent plasma donors (CCP, n = 244) (18, 21) , participants in the Clinical Characterization Protocol for Severe Infectious Diseases (CCPSEI, n = 246) (22) , and HCP (n = 4) (23). All samples were from individuals with a known positive SARS-CoV-2 reverse transcription-PCR (RT-PCR) test result. The majority of the CCP donors had mild disease, with 9% of this cohort reporting hospitalization. Among the CCPSEI cohort, 14% received oxygen therapy, 33% received ventilation, and 13% died. All HCP had mild disease. Additionally, there were 46 HCP who were infected and subsequently vaccinated, 28 with a confirmed PCR date and 18 who were suspected as having prior infection (PCR negative, but symptomatology indicative of an infection). The specificity of the testing algorithm was assessed using 992 samples from prepandemic remnant complete blood count (CBC) samples collected from Johns Hopkins Hospital Emergency Department (JHH ED) patients between December 2015 and January 2016 (24) . Samples for algorithm application. The testing algorithm was subsequently applied to two serosurveys conducted among patients attending the JHH ED from 16 March to 30 April 2020 and from 11 January to 10 March 2021. As previously described in an identity-unlinked seroprevalence study (25) , remnant CBC blood samples from ED patients aged .17 years were collected during the study period. Each sample was assigned a unique study code, processed, and stored at 280°C. Basic patient demographic characteristics (age, sex, race, and ethnicity) were abstracted from the ED administrative database, and all identifiers and protected health information were removed from the data set. Data regarding COVID-19 vaccination status were not available. Laboratory testing was performed on stored specimens after delinking the demographic data set.

Laboratory methods. The testing algorithm required three serologic assays that could differentiate serologic reactivity to SARS-CoV-2 S1, RBD, and nucleocapsid. These assays were limited to standard ELISA and point-of-care assays, as chemiluminescent detection equipment is expensive and not readily available to most laboratories. We selected ELISA-based technologies for the initial high-throughput screening. Confirmatory testing was done with point-of-care assays. Additional information on the assays is available in Table S1 in the supplemental material.

Plasma and serum samples were analyzed using three commercially available serologic assays: the Euroimmun anti-SARS-CoV-2 ELISA (Mountain Lakes, NJ), the CoronaCHEK COVID-19 IgG/IgM rapid test cassette (Hangzhou Biotest Biotech Co. Ltd.), and the Bio-Rad Platelia SARS-CoV-2 total-antibody ELISA (Marnes-la-Coquette, France). Each assay was selected for speed of testing (using an ELISA as an initial screen as the throughput is many times faster than using point-of-care testing), previously determined performance (18, 26) , ease-of-use characteristics (standard ELISA technology, no large pieces of equipment necessary) and availability. The Euroimmun ELISA measures IgG responses to the S1 protein of SARS-CoV-2, whereas the Bio-Rad ELISA measures total antibodies to nucleocapsid. Both ELISAs generate a ratio of the optical density of the sample to that of the control (referred to as a signal-to-cutoff ratio [S/C]). For the Euroimmun and Bio-Rad ELISAs, an S/C of $0.8 was considered a positive result. The CoronaCHEK lateral flow assay (LFA) tests for the presence of both IgM and IgG antibodies to the receptor-binding domain (RBD) of the spike protein. Any visible band was considered a positive result. Each assay was performed according to the manufacturer's instructions.

An algorithm composed of the Euroimmun, Bio-Rad, and CoronaCHEK assays was used to differentiate samples into three groups: previously infected (who may or may not subsequently be vaccinated), vaccinated (who were never infected), and unexposed ( Fig. 1) . All samples were first tested using the Euroimmun ELISA (S1). Next, all positive and indeterminate samples were subsequently tested on CoronaCHEK (RBD). Samples that tested positive on Euroimmun and negative on CoronaCHEK were assumed to be false positives and classified as not previously infected or vaccinated (unexposed). Samples that tested positive on CoronaCHEK were tested with the Bio-Rad Total Ab assay (N). Samples which were reactive by Euroimmun and CoronaCHEK but negative by the Bio-Rad assay were considered vaccinated. Samples with a positive or indeterminate result on the Bio-Rad assay were considered previous infections.

Statistical methods. To evaluate the diagnostic accuracy of the testing algorithm for a particular state (vaccinated or previously infected), the sensitivity for each state was determined from samples with that known status (the training sample sets) ( Table 1 ). Calculation of specificity included all samples from unexposed individuals and the samples from individuals of the other state. Since sample collection had occurred prior to the availability of the COVID-19 vaccines, both previously infected and prepandemic samples were considered negative samples to calculate the sensitivity and specificity of the algorithm for the detection of vaccinated samples. To calculate algorithm sensitivity and specificity for previously infected samples, samples from the vaccinated (known to be uninfected) and prepandemic cohorts were considered negative samples. The 48 samples from individuals known or suspected to be infected and subsequently vaccinated were not included in determining the performance of the algorithm. Statistically significant differences in the ELISA S/C values between vaccinated and previously infected individuals were determined using a t test. Chi-squared and Fisher's exact tests was used to examine the differences in population demographics between the 2020 and 2021 serosurveys. For the JHH ED serosurvey sample sets, factors associated with previous infection or vaccination were assessed with logistic regression.

Samples from vaccinated individuals without prior SARS-CoV-2 infection (n = 428), unvaccinated individuals with PCR-confirmed infection (n = 494), and those seen in the ED prepandemic (n = 992) were tested on all three assays (Fig. 2) . The Euroimmun S1 ELISA was positive for 100% (95% confidence interval [CI], 99.1 to 100.0%), 89% (95% CI, 86.2 to 91.9%), and 3.2% (95% CI, 2.2 to 4.5%) of samples from vaccinated, previously infected, and prepandemic cohorts, respectively. Similarly, for the Bio-Rad N ELISA, 0% (95% CI, 0.0 to 0.7%), 91% (95% CI, 88.2 to 93.5%), and 1.4% (95% CI, 0.7 to 2.4%) were positive for vaccinated, previously infected, and prepandemic cohorts. For the CoronaCHEK RBD assay, 100% (95% CI, 99.1 to 100.0%), 91% (95% CI, 87.8 to 93.1%), and 0.5% (95% CI, 0.2 to 1.2%) had any reactive band for samples from vaccinated, previously infected, and prepandemic cohorts. For samples from vaccinated individuals, algorithm sensitivity and specificity were 100% (95% CI, 99.1 to 100.0%) and 98.9% (95 Cl, 98.2 to 99.3%), respectively (Table 2; Fig. S1a ). For samples from previously infected individuals, algorithm sensitivity and specificity were 84.4% (95% CI, 80.9 to 87.5%) and 100% (95% CI, 99.7 to 100.0%), respectively (Table 3 ; Fig. S1b ).

We investigated whether a two-step algorithm could be used, such as an initial screen with the CoronaCHEK RBD assay followed by the Bio-Rad N ELISA. This two-set algorithm had performance characteristics similar to those of the three-step algorithm described above but increased the time to testing by a factor of 5, as the initial screening with an ELISA is much more efficient than a point-of-care test. For samples from vaccinated individuals, the two-step algorithm sensitivity and specificity were 100% (95% CI, 99.1 to 100.0%) and 98.5% (95 Cl, 97.8 to 99.1%), respectively (Fig. S2a) . For previously infected individuals, algorithm sensitivity and specificity were 87.3% (95% CI, 84.0 to 90.1%) and 100% (95% CI, 99.7 to 100.0%), respectively (Fig. S2b) .

There were significant differences between SARS-CoV-2 serostatus and the level of antibody reactivity to spike and nucleocapsid among the cohorts used for algorithm validation (Fig. 3) . For vaccinated individuals, the median S/C value for antibody reactivity against spike was 8. . Because of the timing of sample collection relative to vaccination, it is very unlikely that these 18 samples represented breakthrough infections. It is more likely that these infections were unconfirmed infections that occurred prior to vaccination. There was little reactivity for samples from prepandemic samples.

Using the testing algorithm, 1,536 JHH ED 2020 samples and 2,824 JHH ED 2021 samples were evaluated. During the two collection periods, combined seroprevalence of antibodies to SARS-CoV-2 from 1.6% (95% CI, 1.1 to 2.5%) to 23.8% (95% CI, 22.2 to 25.4%) (Fig. 4) . During the 7 weeks of the second survey, the prevalence of vaccination significantly increased from 2.8% (95% CI, 0.9 to 6.3%) in mid-January to 11% (95% CI, 8.6 to 13.7%) by mid-March 2021. The age, sex, and race/ethnic demographics of the two survey periods were similar (Table 4) . For both surveys, approximately 27% of participants were $60 years of age, 52% were female, 60% were Black, 26% were white, and 7% were Hispanic. The prev- alence of infection in the spring of 2020 did not vary significantly by age, ethnicity, race, and sex. In contrast, by the spring of 2021, significant differences in infection by age, ethnicity, race, and sex were observed. The prevalence of antibodies to SARS-CoV-2 indicating previous infection or vaccination is presented in Table 4 . White women and men had the lowest prevalence of infection both in 2020 and 2021. In the 2021 survey, white women accounted for 9% of all infections in 2021 but 27% of all vaccinations. For all other groups, the prevalence of exposure to SARS-CoV-2 was higher than the frequency of vaccination. By the spring of 2021, Hispanic patients had the highest evidence of prior SARS-CoV-2 infection within any ethnic group, at 38%.

In the 2021 survey, there were no statistically different rates of infection between age groups (Table 5 ). In contrast, 45-to 59-year-olds were less likely to be vaccinated than the youngest individuals (adjusted odds ratio [aOR] = 0.71; 95% CI, 0.52 to 0.98). Compared to Black women, white women were less likely to be previously infected (aOR, 0.46; 95% CI, We disaggregated the data by sex, race, and ethnicity. In terms of previous infection (Table S2a) , individuals between the ages of 45 to 74 were 22% less likely to have evidence of prior infection than the 18-to 29-year-old JHH ED patients. White individuals were 30% less likely to have been infected than Black individuals. Hispanic individuals had more than three times the burden of infection compared to non-Hispanic individuals, with an aOR of 3.31 (95% CI, 2.16 to 5.07). After adjusting for age and race/ethnicity, women had an increased odds for vaccination compared to men, with an aOR of 1.35 (95% CI, 1.02 to 1.80) ( Table S2b ). In comparison to patients aged 18 to 29, patients aged 45 to 59 years were less likely to be vaccinated, with an aOR of 0.50 (95% CI, 0.31 to 0.80). Furthermore, white patients had more than twice the odds of vaccination compared to Black patients, with an aOR of 2.26 (95% CI, 1.67 to 3.07).

This study describes a method for distinguishing between SARS-CoV-2-vaccinated, previously infected, and uninfected individuals using commercially available serologic assays when no vaccination or infection history is available. The algorithm utilized in this study indicates a 10-fold increase in seropositivity to SARS-CoV-2 infection in the Baltimore metropolitan area from April 2020 to March 2021. Furthermore, this study highlights disparities based on sex and race/ethnicity in SARS-CoV-2 prevalence and vaccine distribution within metropolitan Baltimore during the spring of 2021.

This study followed the work of Suhandynata et al. (27) in the ability to differentiate vaccinated from infected individuals based on antibody responses to the S1 and N proteins of SARS-CoV-2. In contrast to the Suhandynata et al. study, which utilized chemiluminescent assays (Roche Elecsys Anti-SARS-CoV-2 S and N antibody) (27) , we applied more commonly available ELISA and LFA methods. Other chemiluminescent assays, such as the Meso Scale Diagnostics assay, provide testing where multiple antigens (S1, RBD, and N) can be evaluated in one well. This assay relies on chemiluminescent technology, which requires expensive technology not affordable to many laboratories worldwide. We further expanded the study by Suhandynata et al. by using assays that do not need expensive chemiluminescent technology, incorporating a larger validation cohort, and applying the algorithm to population-level surveillance.

This study confirms previous reports of high burden of COVID-19 among the Baltimore Hispanic population (28) . Additionally, the discrepancies in vaccine uptake among racial and ethnic minority groups are clearly demonstrated. While recent data suggest that racial and ethnic gaps in vaccination have narrowed (10), our data from early 2021 suggest that disparities in vaccination were present in the initial stages of the vaccine rollout. Surprisingly, despite prioritizing older Americans during the vaccine rollout (29) , patients older than 60 were as likely to be vaccinated as those between the ages of 18 to 44. This method demonstrated 100% sensitivity in identifying individuals who were fully vaccinated with both the Pfizer and Moderna vaccines. One critical potential limitation to the use of antispike and antinucleocapsid antibody testing to differentiate previously infected from vaccinated individuals is differential loss of antibody reactivity to these two targets. In a cohort of 3,276 health care workers in the United Kingdom, Lumley et al. estimated that anti-nucleocapsid IgG antibodies exhibit a half-life of 85 days from the maximum titer (95% CI, 81 to 90) (30) . In contrast, the half-life of antispike IgG antibodies could not be measured, as 94% of health care workers did not exhibit significant loss during follow-up (30) . Additionally, antinucleocapsid antibody decline was more rapid in younger patients and those with milder symptoms. Thus, in the proposed algorithm, a proportion of previously infected individuals will be misclassified as vaccinated, as antinucleocapsid antibodies wane with time. This effect will be differential by age and initial symptomology. The time to seroreversion of spike and nucleocapsid antibodies in SARS-CoV-2-infected patients is significantly affected by both disease severity and assay platform. The effect of these variations should be considered when interpreting the results of serosurveillance studies.

This study has several additional limitations. We did not test any individuals with known breakthrough infection (vaccinated then infected), nor could we distinguish between previously infected individuals who were and were not subsequently vaccinated. Furthermore, a lack of seroreactivity occurred in a minority of previously infected individuals. The lack of seroconversion in infected individuals has been observed in other studies and occurs most frequently in individuals with asymptomatic infection (31) (32) (33) . Using this testing algorithm, 16% of individuals with a previous positive RT-PCR test were seronegative by the algorithm. Similarly, Self et al. found that in a convenience sample of 156 mildly infected frontline health care personnel, 93.6% experienced a decline in antibody response and 28.2% seroreverted within 60 days (34) . These studies illustrate the difficulty of identifying infected persons several months after infection, especially in cases of mild infection. It should be noted that antibody reactivity is also dependent on the assay used, especially at 6 months after SARS-CoV-2 infection (35) .

Although the correlates of antibody protection for previously infected individuals are not well established (36) , we demonstrated that a serosurvey can be performed to differentiate vaccinated, previously infected, and at-risk unexposed individuals in a population when vaccination or infection history is not available. This information provides evidence for targeted public health intervention in preparation for the continued spread of endemic SARS-CoV-2 infections.

Supplemental material is available online only. SUPPLEMENTAL FILE 1, PDF file, 0.8 MB.

Johns Hopkins Coronavirus Resource Center

Coronavirus disease 2019 case surveillance-United States

The COVID-19 pandemic: a call to action to identify and address racial and ethnic disparities

COVID-19 and African Americans

COVID-19 vaccines

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

Beigel JH, mRNA-1273 Study Group. 2020. An mRNA vaccine against SARS-CoV-2-preliminary report

Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19

Racial/ethnic differences in COVID-19 vaccine hesitancy among health care workers in 2 large academic hospitals

COVID-19 and vaccine hesitancy: a challenge the United States must overcome

Black-white disparities in 2009 H1N1 vaccination among adults in the United States: a cautionary tale for the COVID-19 pandemic

Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019

Unsuspected human immunodeficiency virus in critically ill emergency patients

Parallel declines in HIV and hepatitis C virus prevalence, but not in herpes simplex virus type 2 infection: a 10-year, serial cross-sectional study in an inner-city emergency department

Global surveillance of emerging influenza virus genotypes by mass spectrometry

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers

Vaccine Effectiveness Among Healthcare Personnel Study Team. 2021. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel-33

Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Ambulatory COVID Study Team. 2021. The clinical course of COVID-19 in the outpatient setting: a prospective cohort study

Longitudinal cohort of SARS-CoV-2 previous infection among healthcare workers depicts prolonged antibody durability

The HIV screening cascade: current emergency department-based screening strategies leave many patients with HIV undiagnosed

Johns Hopkins COVID-19 EM Investigators. 2021. Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency department

Evaluation of serological SARS-CoV-2 lateral flow assays for rapid point-of-care testing

SARS-CoV-2 serology status detected by commercialized platforms distinguishes previous infection and vaccination adaptive immune responses

SARS-CoV-2 positivity rate for Latinos in the Baltimore-Washington, DC region

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus

Oxford University Hospitals Staff Testing Group. 2021. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers

Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections

Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories

Diagnostic efficiency of three fully automated serology assays and their correlation with a novel surrogate virus neutralization test in symptomatic and asymptomatic SARS-COV-2 individuals

Decline in SARS-CoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network-12 states

Rodriguez-Barraquer I, Greenhouse B. 2021. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

We acknowledge the staff and patients at the Johns Hopkins Hospital for making this research possible. We thank Morgan Keruly, Ethan Klock, and Olivia Ajayi for technical assistance. We also acknowledge the generosity of the collective community of donors to the Johns Hopkins University School of Medicine and the Johns Hopkins Health System for COVID research.